Photo from Umang Swami/X
May 8, 2024, 07:21
Umang Swami: Prior NHT in patients with MCRPC
Umang Swami, Assistant Professor in the Department of Oncology at Huntsman Cancer Institute, shared on X:
“Most patients (63%) diagnosed with Metastatic castration-resistant prostate cancer (mCRPC) (even in 2023) never received prior Neoadjuvant hormonal therapy (NHT). .
NHT remains the most common therapy in 1L mCRPC (even in patients treated with prior NHT).”
Source: Umang Swami/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 15:10
Feb 25, 2025, 14:12
Feb 25, 2025, 14:04
Feb 25, 2025, 13:56
Feb 25, 2025, 13:46
Feb 25, 2025, 13:38
Feb 25, 2025, 11:33